Want to see IT:PHIL full AI Analyst Report?
Top Page
Philogen SpA
(PHIL)
Select Model
Select Model
Rating:84Outperform
Price Target:
€26.00
▲(10.40% Upside)
Action:Upgraded
Date:07/09/26
The score is driven primarily by strong financial performance (profitability and cash flow surged alongside a low-debt balance sheet), supported by an attractive valuation (low P/E and solid dividend yield). Technicals are constructive with price above key moving averages and positive MACD, though momentum indicators (RSI and Stochastic) are elevated, suggesting higher near-term pullback risk.
Positive Factors
Revenue and Profit Growth
Revenue and net income increased sharply in 2025, showing strong current commercial or partnering execution and greater scale. If this level of activity persists, it can fund development internally and create more resources to advance the targeted-therapy pipeline.
Negative Factors
Historical Earnings Volatility
Losses and negative operating and free cash flow through 2023, followed by an unusually large 2025 improvement, show that financial performance has not been consistently predictable. This makes forward cash generation and earnings power less durable until more periods confirm the trend.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Profit Growth
Revenue and net income increased sharply in 2025, showing strong current commercial or partnering execution and greater scale. If this level of activity persists, it can fund development internally and create more resources to advance the targeted-therapy pipeline.
Read all positive factors
Philogen SpA (PHIL) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€652.12M
Dividend Yield3.11%
Average Volume (3M)18.74K
Price to Earnings (P/E)4.0
Beta (1Y)-0.13
Revenue Growth294.92%
EPS Growth390.98%
CountryIT
Employees214
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)5.68
Shares Outstanding29,242,860
10 Day Avg. Volume22,301
30 Day Avg. Volume18,741
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.51
Price to Sales (P/S)2.99
P/FCF Ratio3.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.41
Revenue Forecast (FY)€31.65M
Philogen SpA Business Overview & Revenue Model
Company Description
Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma ...
How the Company Makes Money
Philogen’s ability to generate revenue is primarily tied to advancing its proprietary drug candidates and monetizing its antibody-targeting technology through partnering. Key potential revenue streams include: (1) Licensing and collaboration incom...
Philogen SpA Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
86
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 314.32M | 74.00M | 23.13M | 23.71M | 2.50M |
| Gross Profit | 271.84M | 54.42M | 5.67M | 10.53M | -8.14M |
| EBITDA | 255.84M | 44.75M | -2.05M | -1.17M | -12.98M |
| Net Income | 229.68M | 45.29M | -6.16M | -5.38M | -15.72M |
Balance Sheet | |||||
| Total Assets | 437.33M | 168.45M | 119.27M | 125.83M | 132.75M |
| Cash, Cash Equivalents and Short-Term Investments | 379.22M | 113.73M | 75.34M | 86.20M | 101.68M |
| Total Debt | 10.88M | 11.54M | 14.91M | 15.76M | 16.49M |
| Total Liabilities | 63.46M | 29.80M | 28.68M | 27.91M | 27.67M |
| Stockholders Equity | 373.86M | 138.66M | 90.59M | 97.92M | 105.09M |
Cash Flow | |||||
| Free Cash Flow | 268.05M | 38.67M | -10.37M | -9.15M | -25.85M |
| Operating Cash Flow | 271.44M | 40.84M | -4.82M | -4.94M | -19.03M |
| Investing Cash Flow | -171.82M | -22.28M | 159.00K | 24.20M | -47.77M |
| Financing Cash Flow | -2.99M | -3.78M | -4.17M | -3.78M | 63.05M |
Philogen SpA Technical Analysis
Negative
23.55
Price Trends
23.37
Negative
23.35
Negative
22.24
Positive
Market Momentum
-0.25
Positive
41.88
Neutral
28.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHIL, the sentiment is Negative. The current price of 23.55 is above the 20-day moving average (MA) of 23.05, above the 50-day MA of 23.37, and above the 200-day MA of 22.24, indicating a neutral trend. The MACD of -0.25 indicates Positive momentum. The RSI at 41.88 is Neutral, neither overbought nor oversold. The STOCH value of 28.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:PHIL.
Philogen SpA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | €652.12M | 4.05 | 63.77% | 3.11% | 294.92% | 390.98% | |
75 Outperform | €10.94B | 21.67 | 24.74% | 2.55% | 9.10% | 22.99% | |
73 Outperform | €4.23B | 23.92 | 13.91% | 1.69% | -3.13% | -22.16% | |
67 Neutral | €1.30B | 14.19 | 17.54% | 1.53% | 2.55% | 22.08% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
43 Neutral | €11.74M | -0.34 | 17.04% | 0.03% | 74.59% | ― |
* General Sector Average
IT:PHIL
Philogen SpA
22.50
-0.36
-1.60%
IT:DIA
DiaSorin S.p.A.
76.80
0.57
0.75%
IT:ELN
El.En. S.p.A.
16.32
5.19
46.60%
IT:FDA
Fidia Spa
0.01
-0.26
-96.27%
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
52.65
1.03
2.00%
IT:ARBS
Arterra Bioscience SpA
3.08
0.47
18.19%
Philogen SpA Corporate Events
Philogen Updates on Modest Progress in Ongoing Share Buyback Program
Sep 28, 2026
Philogen has provided an update on its ongoing share buyback program, reporting the repurchase of 3,766 treasury shares on Euronext Milan between 21 and 25 September 2026 for a total consideration of €84,420.13. These latest transactions rai...
Philogen expands treasury stake with continued share buybacks
Sep 14, 2026
Philogen S.p.A., a biotech group active in oncology and other severe diseases, leverages proprietary antibody and DNA-encoded library technologies to design tumor-targeting therapeutics, aiming to address conditions where current treatments remain...
Philogen Adds to Treasury Stock with Latest Share Buyback Tranche
Sep 7, 2026
Philogen has reported fresh activity under its share buyback program, disclosing the repurchase of 3,626 shares on Euronext Milan between 31 August and 2 September 2026 at an average price of €22.9647, for a total outlay of €83,269.99....
Philogen Reports Mediobanca Share Purchase on Italian Market
Sep 2, 2026
Philogen S.p.A. disclosed a transaction in its listed shares involving Mediobanca S.p.A., a Milan-based financial institution acting in an engagement capacity. The communication relates to Philogen’s ordinary shares, underscoring the company...
Mediobanca Reports Purchase of Philogen Shares on Italian Market
Aug 3, 2026
Philogen S.p.A. disclosed a transaction in its listed shares involving Mediobanca S.p.A., a major Italian financial institution acting under an unspecified engagement. The transaction, executed on July 22, 2026, on the EXM market segment, involved...
Philogen Updates Share Buyback as Treasury Stake Nears 0.9% of Capital
Jul 27, 2026
Philogen S.p.A. has provided an update on its share buyback program, reporting the purchase of 230 treasury shares on Euronext Milan between 20 and 24 July 2026 at an average price of €22.80 per share, for a total outlay of €5,244.00. ...
Philogen resubmits strengthened EMA application for melanoma drug Nidlegy
Jul 27, 2026
Philogen has resubmitted an updated marketing authorization application to the European Medicines Agency for Nidlegy as a neoadjuvant therapy in adult patients with locally advanced, fully resectable melanoma. The dossier is now supported by longe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.